Forbion, a leading European life science venture capital firm, today announced the final close of its new flagship fund, Forbion IV, at €360m in capital commitments, significantly above its original target of €250m. New investors include UK-based Pantheon, Dutch institutions ASR Insurances and the TNO Pension Fund, Nordic investors Formuesforvaltning and KLP, and some undisclosed North American institutional investors. Existing limited partners (LPs) European Investment Fund and development bank KfW also returned as backers of the new fund.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?